Celsion updates recent pipeline developments for GEN-1 immunotherapy program
Celsion reported completion of enrollment of the first cohort of patients in its Phase 1b dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for treatment of newly-diagnosed ovarian cancer patients. February 12, 2016